Biogen Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 10.98B | 10.17B | 9.84B | 9.68B | 9.81B | 1.4% | |
| Cost of Revenue | (2.11B) | (2.28B) | (2.53B) | (2.31B) | (2.90B) | 25.4% | |
Gross Profit | 8.87B | 7.90B | 7.30B | 7.37B | 6.91B | -6.1% | |
| Operating Expenses | |||||||
| Research & Development | (3.40B) | (2.60B) | (2.70B) | (2.49B) | (1.95B) | -21.5% | |
| Selling, General & Administrative | (2.68B) | (2.41B) | (2.50B) | (2.39B) | (2.43B) | 2.0% | |
| General & Administrative | (2.58B) | (2.35B) | (2.43B) | (2.32B) | (2.43B) | 4.9% | |
| Depreciation & Amortization | (487.70M) | (518.40M) | (494.80M) | (673.20M) | (935.40M) | 38.9% | |
Operating Income (EBIT) | 2.79B | 2.89B | 2.10B | 2.49B | 1.88B | -24.6% | |
| Non-Operating Items | |||||||
| Interest Income | 11.00M | 89.30M | 276.50M | 67.60M | 87.80M | 29.9% | |
| Interest Expense | (253.60M) | (246.60M) | (246.90M) | (250.30M) | (246.00M) | -1.7% | |
| Other Income/Expenses (Net) | -1.01B | 705.30M | -800.50M | -584.30M | -476.00M | -18.5% | |
Income Before Tax | 1.78B | 3.59B | 1.30B | 1.91B | 1.40B | -26.5% | |
| Income Tax Expense | (52.50M) | (632.80M) | (135.30M) | (273.80M) | (108.11M) | -60.5% | |
Net Income | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B | -20.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $10 | $21 | $8 | $11 | $9 | -21.0% | |
| Weighted Avg Shares Outstanding | 149.10M | 145.30M | 144.70M | 145.70M | 146.70M | 0.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 149.60M | 146.00M | 145.60M | 145.90M | 146.70M | 0.5% | |
EBITDA | 3.92B | 3.54B | 2.38B | 3.00B | 3.10B | 3.5% |
Explore BIIB
BIIB in the Healthcare
Large Cap